Use of a phosphodiesterase type-5 (PDE5) inhibitor was associated with a lower risk for death and cardiovascular events than alprostadil for the treatment of erectile dysfunction in men with stable coronary artery disease in a large Swedish registry study.
from Google Alert - health https://ift.tt/2OTruep
via IFTTT
0 comments:
Post a Comment